ImmuPharma (LON:IMM) Trading 20.1% Higher - Here's What Happened

Key Points

• ImmuPharma's stock surged by 20.1% during mid-day trading, reaching GBX 13.45 ($0.18), with a significant trading volume of 21,535,730 shares, a 170% increase over average session volume.
• The company reported a quarterly loss of GBX (0.38) earnings per share (EPS) with a net margin of 3,519.56%, while analysts predict an average EPS of -339.0000022 for the current fiscal year.
• ImmuPharma specializes in **peptide-based therapeutics** for autoimmune diseases, with its lead program, Lupuzor™, targeting the treatment of lupus.

ImmuPharma plc (LON:IMM - Get Free Report) was up 20.1% during trading on Friday . The company traded as high as GBX 13.45 ($0.18) and last traded at GBX 13.03 ($0.18). Approximately 21,535,730 shares changed hands during trading, an increase of 170% from the average daily volume of 7,988,423 shares. The stock had previously closed at GBX 10.85 ($0.15).

ImmuPharma Trading Up 28.8%

The firm has a market cap of £69.86 million, a PE ratio of -1,570.67 and a beta of 1.53. The business's 50-day simple moving average is GBX 3.12 and its 200 day simple moving average is GBX 2.91.

ImmuPharma (LON:IMM - Get Free Report) last posted its earnings results on Wednesday, August 6th. The company reported GBX (0.38) EPS for the quarter. ImmuPharma had a net margin of 3,519.56% and a negative return on equity of 131.41%. Analysts expect that ImmuPharma plc will post -339.0000022 earnings per share for the current year.

ImmuPharma Company Profile

ImmuPharma PLC LSE AIM: IMM is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.